Trust Signals
- All efficacy claims are graded by evidence type (human RCT, small human study, animal, in vitro).
- Negative trial outcomes are reported alongside positive ones.
- No affiliate links to peptide vendors. No undisclosed commercial relationships.
- Sources are real, named publications or regulatory documents. No invented citations.
- Speculation is labeled as speculation throughout.
Key Takeaways
- Semaglutide (Wegovy 2.4 mg/week) produced approximately 15% mean body weight loss versus roughly 2.5% placebo in the STEP 1 trial (n=1961, 68 weeks).
- Tirzepatide (15 mg/week) produced approximately 22% mean body weight loss in SURMOUNT-1 (n=2539, 72 weeks), currently the highest human-trial effect size for any fat-loss peptide.
- AOD-9604 failed its Phase 2b and Phase 3 human trials; its rodent data did not translate.
- CJC-1295 and ipamorelin raise GH pulse amplitude in small human studies, but no large RCT has demonstrated clinically meaningful fat loss in non-GH-deficient adults.
- Purity fraud in the research peptide market is well-documented; an independent HPLC COA is the minimum bar for any non-pharmaceutical peptide.
What Is the Best Peptide for Fat Loss?
The best-evidenced peptide for fat loss is semaglutide, a GLP-1 receptor agonist with multiple large RCTs confirming roughly 15% body weight reduction. Tirzepatide edges it on magnitude. Every other marketed fat-loss peptide, including AOD-9604, CJC-1295, and ipamorelin, has substantially weaker or entirely preclinical evidence. If you want results, the evidence hierarchy matters more than the novelty of the compound.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Evidence Ledger: All Major Fat-Loss Peptides Ranked
- How Fat-Loss Peptides Work: Mechanism With Real Numbers
- The Peptides Worth Knowing
- What Most Pages Get Wrong About Research Peptides
- Honest Head-to-Head: Peptides vs. Alternatives
- The Chemistry Behind Storage and Stability Rules
- How to Read a Peptide COA and Product Label
- Side Effects and Failure Modes
- FAQ
- Sources
Evidence Ledger: All Major Fat-Loss Peptides Ranked
| Peptide | Class | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|---|
| Semaglutide | GLP-1 agonist | Multiple large RCTs (STEP 1-4, n >1000 each) | Strong fat/weight loss | High |
| Tirzepatide | GIP/GLP-1 dual agonist | Multiple large RCTs (SURMOUNT-1 to 4) | Very strong fat/weight loss | High |
| Liraglutide | GLP-1 agonist | Large RCTs (SCALE trial program) | Moderate fat/weight loss (~5-8% vs placebo) | High |
| CJC-1295 + Ipamorelin | GHRH analog + GHRP | Small human pharmacokinetic studies; no fat-loss RCT | GH elevation confirmed; fat loss unproven in humans | Low |
| Tesamorelin | GHRH analog | RCTs in HIV-associated lipodystrophy | Reduces visceral fat in specific indication | Moderate (indication-limited) |
| AOD-9604 | GH fragment (hGH 176-191) | Phase 2b/3 human trials (negative) | No significant fat loss in humans | High confidence of no effect |
| BPC-157 | Gastric peptide fragment | Animal models only | No fat-loss signal; tissue repair focus | Very Low for fat loss |
| MOTS-c | Mitochondrial peptide | Animal and early mechanistic human data | Possible metabolic benefit; fat loss unproven in humans | Very Low |
How Fat-Loss Peptides Work: Mechanism With Real Numbers
GLP-1 Receptor Agonists (Semaglutide, Tirzepatide, Liraglutide)
GLP-1 (glucagon-like peptide-1) is a 30-amino-acid incretin hormone secreted by L-cells in the distal small intestine in response to nutrient ingestion. Native GLP-1 has a plasma half-life of roughly 1-2 minutes due to rapid cleavage by dipeptidyl peptidase-4 (DPP-4). Pharmaceutical GLP-1 agonists are engineered to resist this degradation: semaglutide achieves a half-life of approximately 7 days through albumin binding facilitated by a C18 fatty diacid side chain and two amino acid substitutions (Aib8, Arg34). This allows once-weekly dosing.
Fat loss mechanisms are multiple but the primary driver is appetite suppression. GLP-1 receptors are expressed in the hypothalamic arcuate nucleus and nucleus tractus solitarius; receptor activation decreases NPY/AgRP (orexigenic) neuron activity and increases POMC (anorexigenic) signaling. Gastric emptying slows, increasing meal-induced satiety. Energy expenditure increases modestly, though the magnitude is debated. Human trials confirm that caloric intake reduction accounts for the majority of observed weight loss.
In STEP 1 (Wilding et al., NEJM 2021), 1961 adults with BMI 30 or greater received semaglutide 2.4 mg weekly or placebo for 68 weeks. Mean weight reduction was approximately 14.9% in the semaglutide group versus approximately 2.4% in the placebo group. This is a real, reproducible, large-trial number.
Tirzepatide adds GIP receptor agonism. GIP receptors are expressed on adipocytes and may enhance GLP-1-mediated effects on fat oxidation. In SURMOUNT-1 (Jastreboff et al., NEJM 2022), the 15 mg dose group lost a mean of approximately 22.5% body weight versus approximately 2.4% placebo at 72 weeks. Whether the added GIP agonism or simply higher effective GLP-1 receptor stimulation drives the superior effect is still an active research question.
GH-Releasing Peptides (CJC-1295, Ipamorelin)
CJC-1295 is a GHRH (growth hormone-releasing hormone) analog modified with a drug affinity complex (DAC) that binds to serum albumin, extending its half-life from minutes to several days. Ipamorelin is a pentapeptide ghrelin mimetic that stimulates GH release via the GHSR-1a receptor. Used together, they produce supraphysiologic GH pulses.
Teichman et al. (JCEM, 2006) demonstrated that CJC-1295 without DAC increased mean 24-hour GH levels roughly 2-fold and IGF-1 levels by a similar order of magnitude in healthy adults. The critical caveat: elevated GH and IGF-1 do not automatically equal meaningful fat loss in non-GH-deficient people. Fat loss from GH therapy in GH-sufficient adults is modest and comes at the cost of potential insulin resistance, joint pain, and fluid retention at pharmacologic doses. No large, blinded RCT has quantified the fat-loss effect of CJC-1295 plus ipamorelin specifically in healthy, non-GH-deficient adults.
Tesamorelin (FDA-Approved GHRH Analog)
Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy. In that specific population, clinical trials demonstrated statistically significant reductions in visceral adipose tissue, typically measured by CT scan, compared to placebo. Extrapolating this to general obesity is not supported by its trial data. It is included here because it represents the only GHRH-class peptide with meaningful RCT evidence, and that evidence is population-specific.
AOD-9604: Why the Animal Data Did Not Translate
AOD-9604 is a 16-amino-acid fragment of human growth hormone (residues 176-191) that includes the lipolytic domain of hGH but lacks the IGF-1-stimulating domain. In rodent studies, it reduced body fat without effects on blood glucose or IGF-1. Metabolic Pharmaceuticals advanced it to human trials. Phase 2b and Phase 3 trials did not demonstrate significant fat loss versus placebo. The company halted development of AOD-9604 as an obesity drug. The likely explanation is pharmacokinetic: the fragment's short half-life and low bioavailability in humans differs from rodent models, and the lipolytic mechanism mediated by a beta-3 adrenergic receptor-linked pathway that is pharmacologically accessible in rodents does not translate cleanly to humans.
The Peptides Worth Knowing: A Practical Summary
1. Semaglutide (Wegovy/Ozempic)
FDA-approved for chronic weight management (Wegovy) and type 2 diabetes (Ozempic). The highest-quality fat-loss evidence of any peptide class. Available by prescription. Compounded versions exist but carry purity and dosing risks (see label literacy section below).
2. Tirzepatide (Zepbound/Mounjaro)
FDA-approved for obesity (Zepbound) and type 2 diabetes (Mounjaro). Currently shows the largest effect size in human trials. Dual GIP/GLP-1 mechanism. Available by prescription.
3. Tesamorelin
FDA-approved but for a narrow indication. Useful to understand the GHRH-class evidence ceiling. Not a general-purpose fat-loss compound outside its approved use.
4. CJC-1295 / Ipamorelin
Popular in wellness and anti-aging clinics. Evidence of GH elevation is real. Evidence of fat loss in non-deficient adults is absent from large trials. May be reasonable as part of a body composition protocol under medical supervision, with appropriately modest expectations. Not appropriate to present as equivalent to GLP-1 agonists for fat loss.
5. AOD-9604, BPC-157, MOTS-c
Not evidenced for fat loss in humans. Avoid claims to the contrary regardless of vendor marketing language.
What Most Pages Get Wrong About Research Peptides
This is the section commodity pages omit entirely.
Penetration and Bioavailability Limits
Peptides are chains of amino acids. Taken orally, most peptides above 3-4 amino acids are cleaved by gastrointestinal proteases (pepsin, trypsin, chymotrypsin) before reaching systemic circulation. This is why nearly all clinically active fat-loss peptides require subcutaneous or intravenous injection. Any oral peptide product marketed for fat loss is almost certainly degraded in the gut before it can act. The exceptions are very small peptides or those with specific chemical protection; none of the fat-loss peptides discussed here work orally in their native form.
Purity and Sourcing Reality
Research peptides sold online as "not for human use" exist in a regulatory grey area. Independent testing by organizations and journalists has repeatedly found that a meaningful fraction of research peptide products contain less peptide than labeled, are contaminated with residual solvents, or contain incorrect sequences. There is no FDA oversight of these products' manufacturing. A COA from the vendor's in-house lab is not independent verification. Only an HPLC purity percentage and mass spectrometry result from a named third-party laboratory constitutes real quality assurance.
The Compounded Semaglutide Risk
During the FDA-declared shortage of semaglutide, compounding pharmacies legally produced semaglutide. The FDA issued multiple warnings about compounded semaglutide products, including concerns about incorrect dosing (salt forms vs. base forms) and contamination. As of 2025, the FDA declared the shortage resolved for Wegovy and instructed 503B outsourcing facilities to stop producing copies. Patients using compounded semaglutide from unverified sources face real dose uncertainty.
Lean Mass Loss With GLP-1 Agonists
GLP-1 agonist trials demonstrate weight loss that includes both fat mass and lean mass. The lean mass fraction varies but is real. Resistance training and adequate protein intake are recommended during GLP-1 agonist treatment specifically to mitigate lean mass loss. Pages that present GLP-1 agonists as pure fat-loss tools without acknowledging lean mass considerations are incomplete.
Honest Head-to-Head: Peptides vs. Real Alternatives
| Compound | Evidence Level | Mean Weight Loss (Human Trials) | Regulatory Status (US) | Where Peptide Loses |
|---|---|---|---|---|
| Semaglutide 2.4 mg/wk | High (multiple RCTs) | ~15% at 68 weeks | FDA-approved (Wegovy) | Cost; GI side effects; requires prescription |
| Tirzepatide 15 mg/wk | High (multiple RCTs) | ~22% at 72 weeks | FDA-approved (Zepbound) | Cost; GI side effects; requires prescription |
| CJC-1295 + Ipamorelin | Low (no fat-loss RCT) | Unknown (no RCT) | Not FDA-approved; research chemical | Loses to all three FDA-approved options on evidence |
| Phentermine/topiramate (Qsymia) | High (RCTs) | ~8-10% at 56 weeks (Gadde et al., Lancet 2011) | FDA-approved | CNS side effects; controlled substance |
| Orlistat (Xenical) | High (RCTs) | ~3-4% more than placebo | FDA-approved | Smallest effect size of approved options; GI side effects |
| Naltrexone/bupropion (Contrave) | High (RCTs) | ~5% vs placebo at 56 weeks | FDA-approved | Modest effect; psychiatric contraindications |
| AOD-9604 | High confidence of no effect | Not significant vs placebo | Not approved | Loses to placebo in human trials |
The Chemistry Behind Storage and Stability Rules
Peptide bonds are amide linkages between amino acids. These bonds undergo hydrolysis, the addition of water across the bond, at a rate that increases with temperature (Arrhenius relationship), acidity or alkalinity (the rate is lowest near neutral pH), and the presence of divalent metal cations that act as catalytic sites.
Lyophilized (freeze-dried) peptides are stable because removing water suppresses hydrolysis. A lyophilized vial stored at room temperature loses activity slowly over months to years depending on the specific peptide. Once reconstituted in water (typically bacteriostatic water containing 0.9% benzyl alcohol to inhibit microbial growth), hydrolysis begins. Refrigeration at 2-8°C substantially slows but does not stop hydrolysis. Freezing stops it almost entirely but introduces freeze-thaw stress on each warming cycle, which can promote aggregation of larger peptides.
The rule "use reconstituted peptide within 30 days" is not arbitrary; it reflects the practical point at which hydrolytic degradation at refrigerator temperature begins to measurably reduce potency for most peptides. The exact kinetics vary by peptide length, sequence, and excipients, but the 30-day guideline is a reasonable conservative default in the absence of specific stability data.
Heat is the main enemy. Leaving a reconstituted peptide vial in a car on a warm day, even briefly, can substantially accelerate degradation. The same logic applies to the shipping chain: a peptide shipped without cold packs in summer may arrive meaningfully degraded, with no visible sign of this beyond subtle discoloration in extreme cases.
Operational Guide: How to Read a Peptide COA and Product Label
What a Valid COA Must Contain
| COA Element | What to Look For | Red Flag |
|---|---|---|
| HPLC Purity | Greater than 98% purity by HPLC | No percentage given; "in-house" only |
| Mass Spectrometry | Observed MW matches theoretical MW of correct sequence | No MS data; only UV absorbance |
| Testing Laboratory | Named third-party lab, ideally ISO 17025-accredited | Internal lab only; no lab name listed |
| Batch Number | Traceable batch number matching the product label | Generic COA not linked to specific batch |
| Peptide Sequence | Full amino acid sequence listed | Only trade name with no sequence |
Reconstitution Math
A vial labeled "5 mg" of a peptide reconstituted with 2 mL of bacteriostatic water yields a concentration of 2.5 mg/mL (2500 mcg/mL). A 100 mcg dose requires 0.04 mL or 4 units on a 100-unit (1 mL) insulin syringe. Always confirm units: "units" on a U-100 insulin syringe equal 0.01 mL each. Dosing errors from unit-versus-mL confusion are among the most common practical errors with injectable peptides.
What Degradation Looks Like
A properly reconstituted peptide solution should be clear and colorless to very slightly yellow. Visible particulates, cloudiness, or significant yellow-brown color are signs of degradation or contamination. A vial that has been left at room temperature for days after reconstitution should be discarded even if it appears clear.
Side Effects, Contraindications, and Failure Modes
GLP-1 Agonists
The most common adverse effects in STEP trials were gastrointestinal: nausea, vomiting, diarrhea, and constipation. These effects were most prominent during dose escalation. A smaller proportion of participants discontinued treatment due to GI events. Rare but serious concerns include a theoretical risk of thyroid C-cell tumors (seen in rodents at pharmacologic doses; human relevance uncertain and the subject of ongoing registries), pancreatitis (rare, causal relationship not definitively established), and gallbladder disease (rate elevated in some trials). Contraindicated in personal or family history of medullary thyroid carcinoma or MEN2.
GH-Releasing Peptides
Reported adverse effects include fluid retention, carpal tunnel-like symptoms (from fluid shifts), transient increases in hunger (especially acutely with ipamorelin), and at higher doses or in susceptible individuals, worsening insulin sensitivity. Theoretical long-term concern: chronic supraphysiologic GH/IGF-1 exposure; this is not well-characterized in healthy humans using these peptides at doses common in wellness settings.
Universal Injectable Risks
Injection site reactions (pain, bruising, lipohypertrophy with repeated same-site injection), and with non-pharmaceutical peptides, infection risk from non-sterile preparation technique.
Frequently Asked Questions
What is the best peptide for fat loss overall?
By evidence quality, semaglutide (Ozempic/Wegovy) is the best-supported peptide for fat loss, with multiple large human RCTs demonstrating roughly 15% body weight reduction over 68 weeks at the 2.4 mg weekly dose. Tirzepatide shows even larger effect sizes in the SURMOUNT trials. All other peptides marketed for fat loss have far weaker or only preclinical evidence.
Does AOD-9604 actually work for fat loss in humans?
AOD-9604 failed to show significant fat loss versus placebo in its Phase 2b and Phase 3 human trials conducted by Metabolic Pharmaceuticals. The peptide works in rodent models but human evidence is negative. It is not FDA-approved for any indication.
Can CJC-1295 or ipamorelin help with fat loss?
CJC-1295 and ipamorelin increase growth hormone pulse amplitude, which can modestly improve body composition over months. Human trial data are limited to small studies. Any fat loss effect is indirect via GH/IGF-1 axis stimulation and is substantially smaller than GLP-1 agonist effects.
What is the difference between semaglutide and tirzepatide for fat loss?
Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 agonist. The SURMOUNT-1 trial of tirzepatide showed up to roughly 22% mean body weight loss at the 15 mg dose over 72 weeks, exceeding semaglutide's approximately 15% in STEP 1. Both are FDA-approved drugs, not research peptides.
Is BPC-157 useful for fat loss?
No meaningful fat-loss evidence exists for BPC-157 in humans. Its studied applications are tissue repair, gut healing, and tendon regeneration in animal models. It is not a fat-loss peptide.
Are research peptides like CJC-1295 legal to buy?
In the United States, peptides like CJC-1295 and ipamorelin are not FDA-approved drugs. They exist in a regulatory grey area when sold as "research chemicals" but cannot legally be sold for human use, compounded without a prescription, or marketed with therapeutic claims.
How do GLP-1 peptides cause fat loss mechanistically?
GLP-1 receptor agonists slow gastric emptying, suppress appetite via hypothalamic GLP-1 receptors, increase satiety signaling, and modestly raise energy expenditure. The primary driver in human trials is caloric intake reduction, not direct lipolysis.
What does a degraded or low-purity peptide look like?
A degraded peptide vial may show visible particulate matter, cloudiness in a normally clear solution, or yellow-brown discoloration. Low-purity research peptides lack a Certificate of Analysis from an independent HPLC test showing purity above 98% and mass spectrometry confirmation of molecular weight.
How should fat-loss peptides be stored?
Lyophilized (freeze-dried) peptides are stable at room temperature for months but should be stored at 2-8 degrees Celsius to extend shelf life. Once reconstituted in bacteriostatic water, most peptides should be refrigerated and used within 30 days. Heat and repeated freeze-thaw cycles accelerate peptide bond hydrolysis.
Can peptides for fat loss cause muscle loss?
GLP-1 agonists cause predominantly fat mass loss but human trial data show that lean mass loss occurs and accounts for a meaningful fraction of total weight lost, varying by individual, diet, and exercise. GH-releasing peptides like CJC-1295/ipamorelin are theorized to preserve or increase lean mass, but large human trial data confirming this are lacking.
What side effects are common with fat-loss peptides?
GLP-1 agonists most commonly cause nausea, vomiting, constipation, and diarrhea, reported in a substantial proportion of trial participants. GH-releasing peptides can cause water retention, transient hunger, and at higher doses, potential insulin resistance. Injection-site reactions occur with all injectable peptides.
How do I read a peptide Certificate of Analysis (COA)?
A valid COA should show: peptide name and sequence, HPLC purity percentage (ideally above 98%), mass spectrometry result confirming molecular weight matches the theoretical value, batch number, and the testing lab's name. Reject any COA that lists only "in-house" testing with no external lab verification.
Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
- Wadden TA, et al. 68-Week Semaglutide vs. Continued Intensive Behavioral Intervention (STEP 3). NEJM. 2021;384(11):1003-1014.
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805.
- Gadde KM, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER). Lancet. 2011;377(9774):1341-1352.
- Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2012;312(4):380-389.
- U.S. Food and Drug Administration. FDA alerts patients and health care professionals about risks of compounded semaglutide products. FDA.gov. 2024.
- U.S. Food and Drug Administration. Wegovy (semaglutide) Prescribing Information. 2